The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Interesting reading Num4, thanks for posting..
It seems Jak's and Tyk2 seem to be pushing the right buttons, so I'm firmly holding onto my buttons till the end game ;)
https://www.hcplive.com/view/detailing-potential-dermatology-drug-approvals-from-aad-2022
Just wondering what to load my next Stocks and shares ISA allowance with.. ummmmm
https://www.optimistdaily.com/2022/03/anti-inflammatory-molecule-could-revolutionize-asthma-treatment/
The team built on past research that had focused on a protein called JAK1, which plays an important role in driving immune responses by signaling for macrophages (immune cells) to patrol for foreign bodies. This protein, though essential, can sometimes react too fiercely, which then creates unnecessary inflammation. This can lead to conditions like Crohn’s disease, rheumatoid arthritis, and asthma.
One potential solution is a new class of drugs called JAK inhibitors which are comprised of four closely related molecules: JAK1, JAK2, JAK3, and TYK2. In the new study, the Trinity researchers discovered a JAK inhibitor that is naturally produced by our own bodies. This molecule, called itaconate, acts as a sort of off-switch for inflammation by putting the brakes on the overactive macrophages that are stimulated by the overly enthusiastic JAK1. The shutting down of inflammation appears to help against asthma.
So far, the researchers tested an itaconate derivative on mice with severe asthma that previously did not respond to the usual anti-inflammatory steroid treatments. The team found that the molecule decreased activation of JAK1 and was able to reduce the severity of asthma in the mice.
“We have high hopes that new medicines based on itaconate could well have potentially as a wholly new therapeutic approach for treating severe asthma, where there is a pressing need for new treatments,” said the lead author of the study, Dr. Marah Runtsch.
Very interesting read..ASTHMA
Jak1 Tyk2... tyk tock ;)
Domainex will join an existing community of biomedical companies at the campus, including IONTAS, PhoreMost, Sareum and Liminal BioSciences. With only one suite remaining of circa 9000 sqft at The Works, Howard Group is forging ahead with its plans to deliver an additional 95,000 sq ft of labs and offices across three new buildings. With a planning application currently under review, construction is planned to start this summer.
https://www.manufacturingchemist.com/news/article_page/Domainex_opens_dedicated_facility_at_Unity_Campus/198738
https://www.howard-ventures.com/projects/our-projects/unity-campus/
Current life sciences occupiers on the campus include Aqdot, Iontas, Liminal Bioscience and Sareum.
https://www.unitycampus.co.uk/phase-2/
Anyone aware they were there, or has this just happened ?
Interesting post T2, Hbd et all, excuse my lack of knowledge on this but if we were listed on NASDAQ, would our LSE Aim listing go? All my shares are in a UK share dealing ISA...
I believe US markets have tax implication's? (I have only dealt in UK market) Any helpful replies appreciated..
Due to the COVID-19 pandemic, the global Tyrosine Kinase JAK Inhibitors market size is estimated to be worth USD 47210 million in 2022 and is forecast to a readjusted size of USD 550830 million
https://www.marketwatch.com/press-release/tyrosine-kinase-jak-inhibitors-market-growth-2022-with-competitive-landscape-industry-size-scope-share-top-manufacturers-trends-and-forecast-to-2028-2022-02-07
wont be long before one of Sareum's molecule's is racking it in ;)
dexamethasone, dexamethasone, dexamethasone
Just a waiting game for Sareum ;)
https://www.msn.com/en-gb/health/medical/covid-drugs-blueprint-will-transform-treatments-for-heart-disease-dementia-and-cancer/ar-AAT6drg?ocid=entnewsntp
https://www.edisongroup.com/edison-open-house-global-healthcare-2022/
Tox results Monday would give this presentation a massive boost
Brighty1, think they already have, I emailed GSK (directorships) last year, and Timbo replied!!
Yep, Timbo replied, we are more than capable..... Which I'm sure if a few others had emailed them, would have had the same kinda response?? ;)
Anyone...
good things come to those that wait, patience is the key, followed by biochemistry ;)
In depth info...
https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwj9ydaclbn1AhWXQUEAHUXoCsQQFnoECA0QAQ&url=https%3A%2F%2Fwww.mdpi.com%2F2073-4409%2F11%2F2%2F306&usg=AOvVaw1cC1a9j4KMaWSfL_Ioya4C
news can drop anytime, keep hold of those golden tickets ;)
These companies are all part of the "drug manufacturers - major" industry.
Well well well, nice to see our little Sareum on their list ;)
https://www.marketbeat.com/stocks/LON/GSK/competitors-and-alternatives/
TARGETING IMMUNE PATHWAYS TO TREAT COVID-19 AND OTHER ACUTE VIRAL LUNG INFECTIONS
good read, very detailed and were are in the driving seat for potential treatments, 1801 needs trials to prove its worth, were the best out there (that I know off!!) ... licencing deal or TO imminent ;)
https://www.science.org/doi/10.1126/sciimmunol.abm5505
GLA Invested
Hope all had an enjoyable break, and are fully refreshed
Apologies if already posted..
https://www.guidelines.co.uk/news/uk-researchers-find-way-to-boost-emerging-breast-cancer-drugs-effectiveness/456673.article
GLA Invested ;)
https://www.thearmchairtrader.com/sareum-holdings-share-price-forecast-december/
nothing negative for me, great RNS and Sareum will be flourishing come spring;)
WHO the Dickins would want to be out of Sareum now and not alone next year!!
GLA Invested